TY - JOUR
T1 - A Comprehensive Analysis of a Prospective Multidisciplinary Peer Review Process Before Radiation Therapy Simulation
AU - Kotecha, Rupesh
AU - LeGrand, Lorrie A.
AU - Valladares, Maria A.
AU - Castillo, Andrea M.
AU - Rubens, Muni
AU - Quintana, Gabriella
AU - Chisem, Monique
AU - Appel, Haley
AU - Chuong, Michael D.
AU - Hall, Matthew D.
AU - Contreras, Jessika A.
AU - Fagundes, Marcio
AU - Gutierrez, Alonso
AU - Mehta, Minesh P.
N1 - Funding Information:
The authors appreciate the individuals who were instrumental to the creation of the “morning huddle” operations meeting and their participation, including Joseph Panoff, Noah Kalman, Maria-Amelia Rodrigues, Albert Lewin, Steven Olszewski, Andre Abitbol, Mayney Gavilondo, George Godfrey, Steven Holan, Michelle Ryder, Ulrich Ramos, Kristin Morris, Gus Luciani, Ranjini Tolakanahalli, D Jay Wieczorek, Lauren Suarez, Michael Rawlins, and Maytee Diaz-Williams. The authors appreciate Lisa Rosen for her assistance with a medical writing review. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Disclosures: Dr Kotecha reports honoraria from Elsevier, Elekta AB, Accuray Inc, and Novocure Inc; and research support from Novocure Inc, Medtronic Inc, and Blue Earth Diagnostics Limited. Dr Chuong reports fees from speakers bureau: ViewRay, Sirtex; medical advisory board: ViewRay, Advanced Accelerator Applications; and research support: ViewRay, AstraZeneca. Dr Hall reports honorarium from Accuray Inc; and research support from Live Like Bella Pediatric Research Initiative, Florida Department of Health, grant 8LA04. Dr Fagundes reports consulting fees from Boston Scientific. Dr Gutierrez reports fees from speakers bureau: ViewRay. Dr Mehta reports consulting fees for Karyopharm, Tocagen, Astra-Zeneca, Blue Earth Diagnostics, Celgene, and Abbvie; board of directors: Oncoceutics.
Funding Information:
Disclosures: Dr Kotecha reports honoraria from Elsevier, Elekta AB, Accuray Inc, and Novocure Inc; and research support from Novocure Inc, Medtronic Inc, and Blue Earth Diagnostics Limited. Dr Chuong reports fees from speakers bureau: ViewRay, Sirtex; medical advisory board: ViewRay, Advanced Accelerator Applications; and research support: ViewRay, AstraZeneca. Dr Hall reports honorarium from Accuray Inc; and research support from Live Like Bella Pediatric Research Initiative, Florida Department of Health, grant 8LA04. Dr Fagundes reports consulting fees from Boston Scientific. Dr Gutierrez reports fees from speakers bureau: ViewRay. Dr Mehta reports consulting fees for Karyopharm, Tocagen, Astra-Zeneca, Blue Earth Diagnostics, Celgene, and Abbvie; board of directors: Oncoceutics.
Publisher Copyright:
© 2020 American Society for Radiation Oncology
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Purpose: Although peer review in radiation oncology (RO) has been recommended to improve quality of care, an analysis of modifications resulting from an RO multidisciplinary presimulation standardized review process has yet to be empirically demonstrated. Methods and Materials: A standardized simulation directive was used for patients undergoing simulation for external beam radiation therapy at a single tertiary care institution. The simulation directives were presented, and all aspects were reviewed by representatives from key RO disciplines. Modifications to the original directives were prospectively captured in a quality improvement registry. Association between key variables and the incidence of modifications were performed using Fisher exact test and t test. Results: A registry of 500 consecutive simulations for patients undergoing radiation therapy was reviewed. A median of 105 simulations occurred per month. All simulation directives were entered by a physician a median of 3 days before simulation (range, 1-76 days). The treatment intent was curative for 269 patients (53.8%), palliative for 203 patients (40.6%), and benign for 3 patients (0.6%). Twenty-five (5%) patients did not have a treatment intent selected. Based on RO multidisciplinary review, 105 directives (21%) were modified from the original intent, with 29 (5.8%) requiring more than 1 modification. A total of 149 modifications were made and categorized as changes to patient positioning and immobilization (n = 100, 20%), treatment site and care path (n = 34, 6.8%), simulation coordination activities (n = 6, 1.2%), and treatment technique and planning instructions (n = 9, 1.8%). A higher proportion of modifications occurred at the time of multidisciplinary review in patients receiving more complex treatments (intensity modulated radiation therapy/stereotactic radiosurgery/stereotactic body radiation therapy [IMRT/SRS/SBRT] vs 3-dimensional radiation therapy [3DCRT] radiation therapy, 25% vs 16%, P < .025). Conclusions: Given the complexity of radiation therapy simulation, standardization of directives with prospective RO multidisciplinary presimulation peer review is critical to optimizing department processes and reducing errors. Approximately 1 in 5 patients benefits from this peer review process, especially patients treated with IMRT/SRS/SBRT.
AB - Purpose: Although peer review in radiation oncology (RO) has been recommended to improve quality of care, an analysis of modifications resulting from an RO multidisciplinary presimulation standardized review process has yet to be empirically demonstrated. Methods and Materials: A standardized simulation directive was used for patients undergoing simulation for external beam radiation therapy at a single tertiary care institution. The simulation directives were presented, and all aspects were reviewed by representatives from key RO disciplines. Modifications to the original directives were prospectively captured in a quality improvement registry. Association between key variables and the incidence of modifications were performed using Fisher exact test and t test. Results: A registry of 500 consecutive simulations for patients undergoing radiation therapy was reviewed. A median of 105 simulations occurred per month. All simulation directives were entered by a physician a median of 3 days before simulation (range, 1-76 days). The treatment intent was curative for 269 patients (53.8%), palliative for 203 patients (40.6%), and benign for 3 patients (0.6%). Twenty-five (5%) patients did not have a treatment intent selected. Based on RO multidisciplinary review, 105 directives (21%) were modified from the original intent, with 29 (5.8%) requiring more than 1 modification. A total of 149 modifications were made and categorized as changes to patient positioning and immobilization (n = 100, 20%), treatment site and care path (n = 34, 6.8%), simulation coordination activities (n = 6, 1.2%), and treatment technique and planning instructions (n = 9, 1.8%). A higher proportion of modifications occurred at the time of multidisciplinary review in patients receiving more complex treatments (intensity modulated radiation therapy/stereotactic radiosurgery/stereotactic body radiation therapy [IMRT/SRS/SBRT] vs 3-dimensional radiation therapy [3DCRT] radiation therapy, 25% vs 16%, P < .025). Conclusions: Given the complexity of radiation therapy simulation, standardization of directives with prospective RO multidisciplinary presimulation peer review is critical to optimizing department processes and reducing errors. Approximately 1 in 5 patients benefits from this peer review process, especially patients treated with IMRT/SRS/SBRT.
UR - http://www.scopus.com/inward/record.url?scp=85097220566&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2020.10.012
DO - 10.1016/j.prro.2020.10.012
M3 - Article
C2 - 33197645
AN - SCOPUS:85097220566
SN - 1879-8500
VL - 11
SP - e366-e375
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 4
ER -